This is a one month pre post intervention study. Subjects with diabetic macular edema were given intravitreal anti VEGF (Aflibercept) injection. Central retinal thickness, macular electrophysiology, and visual acuity were observed one week and one month after injection was given to the eye to describe early anatomical, physiological, and clinical changes. We hypothesized that changes to these outcomes can be found and documented.
Study Type
INTERVENTIONAL
Allocation
NA
Purpose
TREATMENT
Masking
NONE
Enrollment
36
Intravitreal Aflibercept injections were performed by vitreoretinal consultant at the place of study.
Dept. of Ophthalmology, Faculty of Medicine Universitas Indonesia, RSCM Kirana
Jakarta Pusat, DKI Jakarta, Indonesia
Central macular thickness
Central macular thickness (CMT) measured by Cirrus® HD OCT, Carl Zeiss, Germany \[in µm\]
Time frame: One month after intravitreal Aflibercept injection
Central macular thickness
Central macular thickness (CMT) measured by Cirrus® HD OCT, Carl Zeiss, Germany \[in µm\]
Time frame: One week after intravitreal Aflibercept injection
Amplitude of P1 wave
Amplitude of P1 wave in multifocal electroretinogram (MfERG) measured by Electroretinography (Vision Monitor MonPackONE, Metrovision, France) \[in nV/deg2\]
Time frame: One week after intravitreal Aflibercept injection
Amplitude of P1 wave
Amplitude of P1 wave in multifocal electroretinogram (MfERG) measured by Electroretinography (Vision Monitor MonPackONE, Metrovision, France) \[in nV/deg2\]
Time frame: One month after intravitreal Aflibercept injection
Amplitude of N1 wave
Amplitude of N1 wave in MfERG measured by Electroretinography (Vision Monitor Monpack one, Metrovision, France) \[in nV/deg2\]
Time frame: One week after intravitreal Aflibercept injection
Amplitude of N1 wave
Amplitude of N1 wave in MfERG measured by Electroretinography (Vision Monitor Monpack one, Metrovision, France) \[in nV/deg2\]
Time frame: One month after intravitreal Aflibercept injection
Amplitude of N2 wave
Amplitude of N2 wave in MfERG measured by Electroretinography (Vision Monitor Monpack one, Metrovision, France) \[in nV/deg2\]
Time frame: One week after intravitreal Aflibercept injection
Amplitude of N2 wave
Amplitude of N2 wave in MfERG measured by Electroretinography (Vision Monitor Monpack one, Metrovision, France) \[in nV/deg2\]
Time frame: One month after intravitreal Aflibercept injection
Implisit time of P1 wave
Implisit time of P1 wave in MfERG measured by Electroretinography (Vision Monitor Monpack one, Metrovision, France) \[in nV/deg2\]
Time frame: One week after intravitreal Aflibercept injection
Implisit time of P1 wave
Implisit time of P1 wave in MfERG measured by Electroretinography (Vision Monitor Monpack one, Metrovision, France) \[in nV/deg2\]
Time frame: One month after intravitreal Aflibercept injection
Implisit time of N1 wave
Implisit time of N1 wave in MfERG measured by Electroretinography (Vision Monitor Monpack one, Metrovision, France) \[in nV/deg2\]
Time frame: One week after intravitreal Aflibercept injection
Implisit time of N1 wave
Implisit time of N1 wave in MfERG measured by Electroretinography (Vision Monitor Monpack one, Metrovision, France) \[in nV/deg2\]
Time frame: One month after intravitreal Aflibercept injection
Implisit time of N2 wave
Implisit time of N2 wave in MfERG measured by Electroretinography (Vision Monitor Monpack one, Metrovision, France) \[in nV/deg2\]
Time frame: One week after intravitreal Aflibercept injection
Implisit time of N2 wave
Implisit time of N2 wave in MfERG measured by Electroretinography (Vision Monitor Monpack one, Metrovision, France) \[in nV/deg2\]
Time frame: One month after intravitreal Aflibercept injection
Best corrected visual acuity
Best corrected visual acuity (BCVA) measured by ETDRS chart \[in LogMAR\]
Time frame: One week after intravitreal Aflibercept injection
Best corrected visual acuity
Best corrected visual acuity (BCVA) measured by ETDRS chart \[in LogMAR\]
Time frame: One month after intravitreal Aflibercept injection
Best corrected visual acuity (number of letters)
BCVA (number of letters) measured by ETDRS chart \[in number of letters\]
Time frame: One week after intravitreal Aflibercept injection
Best corrected visual acuity (number of letters)
BCVA (number of letters) measured by ETDRS chart \[in number of letters\]
Time frame: One month after intravitreal Aflibercept injection
Uncorrected visual acuity
Uncorrected visual acuity (UCVA) measured by ETDRS chart \[in LogMAR\]
Time frame: One week after intravitreal Aflibercept injection
Uncorrected visual acuity
Uncorrected visual acuity (UCVA) measured by ETDRS chart \[in LogMAR\]
Time frame: One month after intravitreal Aflibercept injection
Uncorrected visual acuity (number of letters)
UCVA (number of letters) measured by ETDRS chart \[in number of letters\]
Time frame: One week after intravitreal Aflibercept injection
Uncorrected visual acuity (number of letters)
UCVA (number of letters) measured by ETDRS chart \[in number of letters\]
Time frame: One month after intravitreal Aflibercept injection
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.